Medicologic has received the CIR (credit d’impôt recherche) approval by the French Ministry of Research and Higher Education as one of very few Scandinavian med-tech consultancies.
The tax credit amount given by the French authorities is adjusted according to the degree of basic research and novelty of the R&D, but in some instances it can be the full project costs.
Therefore, this should motivate Medicologic clients with plans in France to look into the possibilities of reducing overall R&D spending.
Martin Thomsen, COO of Medicologic explains: “We are really proud of this stamp of approval – owing to a consistent and extensively documented R&D strategy it shows the high standards of our R&D expertise. I sincerely hope even more clients will wish to engage in new exciting projects in France together with Medicologic.”
Medicologic is a consultancy focused on medical devices for the med-tech as well as pharma industry which currently is undergoing a transformation from pure drugs to different kinds of drug/device combinations – not least driven by the biosimilar evolution. Several clients are already benefitting from Medicologic’s many years of experience in the industry – providing R&D expertise as well as global support for RA and QA, which most often is closely linked to even the early development phases.
For more information:
Chief Operating Officer, Research & Development
Direct (+45) 22 47 72 12